Quantcast
Last updated on April 18, 2014 at 7:29 EDT

Latest Progenics Pharmaceuticals Inc. Stories

2012-12-17 08:25:53

GAITHERSBURG, Md., Dec. 17, 2012 /PRNewswire/ -- MedImmune, the global biologics arm of AstraZeneca, announced that it has signed an in-licensing agreement with Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) for Progenics' Clostridium difficile late-stage preclinical program. The agreement was led by MedImmune's Infectious Diseases & Vaccines Innovative Medicines (iMed) Unit. Clostridium difficile infections are the leading cause of hospital-acquired bacterial infections in the U.S. and...

2008-11-04 09:00:05

Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced the selection of a proprietary small-molecule drug candidate, designated PRO 206, for clinical development as a treatment of hepatitis C virus (HCV) infection. Pre-clinical results supporting the development of PRO 206 were presented today at the annual meeting of the American Association for the Study of Liver Diseases (AASLD) in San Francisco. PRO 206 is an orally available viral-entry inhibitor, designed to prevent HCV from...

2008-10-26 12:00:10

Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced positive interim results from two separate phase 2 clinical trials of PRO 140 for the treatment of HIV infection. Both intravenous and subcutaneous forms of PRO 140, a novel viral-entry inhibitor, exhibited potent and prolonged activity as measured by reductions in plasma levels of virus in individuals with HIV infection. Interim results (based on the first 15 of 31 patients treated) from the study of intravenous PRO 140 were...

2008-10-16 21:00:19

Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) and Ono Pharmaceutical Co., Ltd., Osaka, Japan (OSE-TYO: 4528) today announced an exclusive license agreement under which Ono has acquired the rights to RELISTOR(R) (methylnaltrexone bromide) in Japan, where it plans to develop and commercialize the U.S.-approved drug for the treatment of opioid-induced constipation. RELISTOR is being developed and commercialized in the rest of the world by Progenics and Wyeth Pharmaceuticals, a division of Wyeth...

2008-10-02 09:00:07

Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced the completion of enrollment in two, phase 2 clinical studies of PRO 140, an investigational drug that is being developed for treatment of human immunodeficiency virus (HIV) infection. The phase 2 studies are separately evaluating intravenous and subcutaneous forms of PRO 140. The Company also reported that interim antiviral and tolerability data from the phase 2 study of intravenous PRO 140 have been selected for presentation in...

2008-09-08 09:00:52

Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced the initiation of a phase 1 dose-escalation clinical study of its prostate-specific membrane antigen (PSMA) antibody-drug conjugate (ADC). PSMA ADC is an investigational therapy that combines a prostate-cancer antibody with a cancer drug. Unlike traditional chemotherapy, PSMA ADC is designed to deliver the drug selectively to prostate cancer cells by targeting a surface protein, PSMA. The clinical study will include patients with...

2008-08-08 09:01:34

Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced its results of operations for the second quarter and first half of 2008. Revenues for the second quarter ended June 30, 2008 totaled $28.6 million compared to $25.5 million for the same quarter in 2007. For the first half of 2008, Progenics reported revenues of $43.3 million compared to $43.1 million for the comparable period in 2007. Revenues primarily reflect reimbursement by the Company's collaborator, Wyeth, for...

2008-07-03 15:00:41

Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), and Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX), today announced that the companies have received marketing approval for RELISTOR(TM) (methylnaltrexone bromide) subcutaneous injection from the European Commission. RELISTOR is now approved in the 27 member states of the European Union as well as Iceland, Norway, and Liechtenstein for the treatment of opioid-induced constipation (OIC) in advanced illness patients who are receiving...